Superluminal Medicines
PrivateLast Round
Series B
Sep 3, 2026
Total Funding Raised
$213M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Superluminal Medicines operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in September 2026.
Superluminal Medicines is a biotechnology company that leverages generative biology, machine learning, and structural biology to accelerate the discovery and development of small molecule therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Superluminal Medicines Comparables
Compare Superluminal Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deep Apple Therapeutics | 87% | |
| Genesis Therapeutics | 86% | |
| Charm Therapeutics | 85% |
For institutional investors. Book with your work email.
Superluminal Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 3, 2026 | ||||
| Strategic | Aug 14, 2025 | ||||
| Series A | Sep 9, 2024 | ||||
| Seed | Aug 28, 2023 |
For institutional investors. Book with your work email.
Superluminal Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Seed, Series A |
| Perceptive Advisors | Series B |
| Gaingels | Seed, Series B, Series A |
| Deep Track Capital | Series B |
| NVentures | Series B |
| Catalio Capital Management | Series B, Series A |
| BVF Partners L.P. | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
$60M round led by BVF Partners L.P.
- Aug 25, 2026
Grew 22% QoQ, from 49 to 60 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 4, 2026
Superluminal Medicines, Inc. develops a drug discovery platform that combines artificial intelligence and machine learning, protein dynamics, structural biology, Cryo-EM, and GPCR-focused drug design to identify small-molecule candidates against challenging GPCR targets.
- is_developingSep 4, 2026
Superluminal Medicines, Inc. maintains collaborations with pharmaceutical partners, including Eli Lilly and Company, to develop small molecule therapeutics targeting undisclosed GPCRs for cardiometabolic diseases and obesity.
- is_developingSep 4, 2026
United States-based Superluminal Medicines, Inc. is developing its MC4R agonist for rare genetic forms of obesity, including Bardet-Biedl syndrome and hypothalamic obesity, and plans to advance it into Phase I trials by 2026.
- receives_financingSep 4, 2026
Superluminal Medicines, Inc. receives an oversubscribed $60M Series B financing led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors, on Sep 3rd '26 in Massachusetts to support a planned Phase 1 trial for rare genetic forms of obesity by the end of 2026 and expand its GPCR discovery platform.
For institutional investors. Book with your work email.
Superluminal Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Superluminal Medicines's valuation, stock price, and market status.
Is Superluminal Medicines a public or private company?
Superluminal Medicines is a private company.
What is the current stock price of Superluminal Medicines?
Superluminal Medicines is a private company, so its shares have no public market price. Caplight tracks Superluminal Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Superluminal Medicines worth (valuation)?
Valuation information for Superluminal Medicines is not publicly available.
Can I buy Superluminal Medicines stock?
Superluminal Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Superluminal Medicines's last funding round?
Superluminal Medicines's most recent funding round was Series B on September 3, 2026.
Who are the main investors in Superluminal Medicines?
Key investors in Superluminal Medicines include RA Capital Management, BVF Partners L.P..
Will Superluminal Medicines IPO soon?
No public IPO plans have been announced for Superluminal Medicines.
How can I track Superluminal Medicines secondary market activity?
Caplight tracks bids, offers, and trades in Superluminal Medicines's shares on secondary markets.